Evaggelia Apostolidou

Evaggelia Apostolidou

Auto-generated profile, based on publicly available information

Evaggelia Apostolidou

Allergy and Clinical Immunology Private Practice Thessaloniki Greece

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2024 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
NPNikolaos G. Papadopoulos
Nikolaos G. Papadopoulos
EAEvaggelia Apostolidou
Evaggelia Apostolidou
MMMichael Miligkos
Michael Miligkos
PXPARASKEVI XEPAPADAKI
PARASKEVI XEPAPADAKI
Wheezing is the cardinal symptom of asthma; its presence early in life, mostly caused by viral infections, is a major risk factor for the establishment of persistent or recurrent disease. Early‐life wheezing and asthma exacerbations are triggered by common respiratory viruses, mainly rhinoviruses (RV), and to a lesser extent, respiratory syncytial virus, parainfluenza, human metapneumovirus, coronaviruses, adenoviruses, influenza, and bocavirus. The excess presence of bacteria, several of which are part of the microbiome, has also been identified in association with wheezing and acute asthma exacerbations, including haemophilus influenza, streptococcus pneumoniae, moraxella catarrhalis, mycoplasma pneumoniae, and chlamydophila pneumonia. While it is not clear when asthma starts, its characteristics develop over time. Airway remodeling already appears between the ages of 1 and 3 years of age even prior to the presence of atopic inflammation or an asthma diagnosis. The role of genetic defect or variations hampering the airway epithelium in response to environmental stimuli and severe disease morbidity are now considered as major determinants for early structural changes. Repeated viral infections can induce and perpetuate airway hyperresponsiveness. Allergic sensitization, that often precedes infection‐induced wheezing, shifts inflammation toward type‐2, while common respiratory infections themselves promote type‐2 inflammation. Nevertheless, most children who wheeze with viral infections during infancy and during preschool years do not develop persistent asthma. Multiple factors, including illness severity, viral etiology, allergic sensitization, and the exposome, are associated with disease persistence. Here, we summarize current knowledge and developments in infection epidemiology of asthma in children, describing the known impact of each individual agent and mechanisms of transition from recurrent wheeze to asthma.

16 December 2025 in Allergy
Verified
Journal Article
Open access
CRCarlo Maria Rossi
Carlo Maria Rossi
ITIngrid Terreehorst
Ingrid Terreehorst
EAEvaggelia Apostolidou
Evaggelia Apostolidou
Martina VottoMartina Votto
Martina Votto
ABArzu Bakirtas
Arzu Bakirtas
Constantinos PitsiosConstantinos Pitsios
Constantinos Pitsios
The European Academy of Allergy and Clinical Immunology (EAACI) established a Task Force to assess the existing data on the relationship between eosinophilic esophagitis (EoE) and allergen immunotherapy (AIT). This systematic review and meta‐analysis aimed to study the incidence of confirmed EoE, developing as a side effect of AIT to food or airborne allergens, following the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis (PRISMA) 2020 guidelines. The literature search was performed in three databases (PubMed, Embase and Scopus). Databases were searched from inception to March 31st, 2023. A total of 17 studies met the criteria for inclusion in the review. Fifteen studies, comprising 3,302 patients, were on food desensitization, and the overall estimate of EoE incidence, combining the results of these individual studies, was 2.31% (95% CI 1.45, 3.36). Registered data reported de novo cases of eosinophilic esophagitis, and its diagnosis was usually made during the maintenance phase of food desensitization. With the adopted searching strategy, only two studies on sublingual immunotherapy with aeroallergens meeting the inclusion criteria were retrieved, comprising 1,436 patients and not reporting cases of EoE. The meta‐analysis showed that the development of EoE is a common adverse effect of oral immunotherapy with food allergens, whereas it is uncommon during sublingual immunotherapy with aeroallergens. Trial Registration: PROSPERO: CRD42023425917

18 June 2026 in Clinical and Translational Allergy
Verified
Journal Article
Open access
Martina VottoMartina Votto
Martina Votto
GRGeorgios Rentzos
Georgios Rentzos
DADarío Antolín-Amérigo2
Darío Antolín-Amérigo2
BRBarbara Rymarczyk
Barbara Rymarczyk
GKGeorge Konstantinou
George Konstantinou
Constantinos PitsiosConstantinos Pitsios
Constantinos Pitsios
Background: Multiple routes of allergen immunotherapy (AIT) are approved for several IgE‐mediated allergic diseases; however, the use of AIT in eosinophilic esophagitis (EoE) remains controversial and is supported by limited evidence. This review, conducted within the frame of an EAACI Task Force, aims to systematically evaluate the use of AIT as a potential treatment for EoE. Methods: The protocol was registered and prepared in accordance with PRISMA guidelines. The literature search was conducted across three online databases (PubMed, Embase, and Scopus) and included studies published through January 31 st , 2025. Risk of Bias was assessed for each eligible study. Results: Four articles met the inclusion criteria. Three articles evaluated EPIT for milk‐induced EoE in pediatric patients, all from the SMILEE (Study of Efficacy and Safety of Viaskin Milk for milk‐induced EoE) trial and its extensions. These included a randomized, placebo‐controlled trial, its open‐label extension, and a pilot immunological study. The SMILEE trial found no statistically significant difference in tissue eosinophilia between the active (EPIT) and control (placebo) arms in the intention‐to‐treat population, while 47% of treated EoE patients tolerated milk without recurrence of esophageal eosinophilia. This finding was further supported by a subsequent open‐label study with a 2‐year follow‐up. In the third publication, the researchers found that EPIT was associated with decreased Th2‐related transcripts and increased regulatory T‐cell‐associated transcripts. Only one eligible study evaluated the use of SCIT for treating EoE. It was a retrospective case‐control study reporting that SCIT had a neutral effect and yielded inconclusive findings regarding the course of EoE. Conclusion: There is insufficient high‐quality evidence to support the effectiveness of alternative routes of AIT for the treatment of EoE, either as an add‐on or a standalone treatment.